Global Myelodysplastic Syndrome (MDS) Drugs Market Research Report: Information by Type (Chemotherapy, Immunomodulatory Drugs and others), Type of Syndrome (Metals & Alloys, Bioabsorbable, Ceramics, Polymers and others), Application (Refractory Cytopenia with Multilineage Dysplasia, Refractory Anemia, Refractory Anemia with Excess Blasts, Refractory Anemia with Ringed Sideroblasts, Refractory Cytopenia with Multilineage Dysplasia and others), Route of Administration (Oral, Parenteral and others), End User (Hospitals, Clinics, Ambulatory Surgical Centers and others) and Region - Global Forecast till 2025
Myelodysplastic syndrome (MDS) are a group of cancers in which blood cells in the bone marrow do not mature making it susceptible to other diseases. When left untreated, MDS can expand to a type of cancer affecting the bone marrow cells known as acute myeloid leukemia (AML). The global myelodysplastic syndrome drugs market report by Market Research Future (MRFR) consists of the various developments in drug discovery, moves by existing players, and other pertinent factors.
Myelodysplastic Syndrome (MDS) Drugs Market Overview
The Global MDS Drugs Market Analysis is estimated to reach a significant value by showcasing a CAGR of 10.1% during the forecast period (2018-2025). It stood at USD 1,581.59 million in 2018. Rise in the number of clinical trials for testing the effects of new drugs in combination with chemotherapy can drive the market growth. Approval of decitabine, a product of Lupin Ltd, by the U.S. FDA is an indicator of the acceptance of new drugs by the market.
The rising numbers of the geriatric populace, regulatory approvals, and advocation of clinical trials pertaining to MDS are other major drivers of the global myelodysplastic syndrome drugs market. Improvement of healthcare services by cancer centers and development of novel therapeutics can fuel the market growth successfully till 2025.
But adverse effects of the drugs and risk of infections during blood transfusions can impede the market growth.
Myelodysplastic Syndrome (MDS) Drugs Market Competition Outlook
Sandoz, Otsuka America Pharmaceutical Inc., Celgene Europe Limited, Lupin Ltd Corporation, Shilpa Medicare Limited, Celgene Corporation, Johnson & Johnson, Reddy's Laboratories, Inc., Sun Pharmaceutical Industries Inc., and BluePoint Laboratories are prominent names in the global myelodysplastic syndrome drugs market.
Myelodysplastic Syndrome (MDS) Drugs Industry News
Onconova Therapeutics Inc has decided to collaborate with Mission Bio for using the latter’s platform for providing breakthrough treatments for MDS. The company plans to use it to study the effects of its targeted therapy, Rigosertib on single-cell DNA analysis.
Myelodysplastic Syndrome (MDS) Drugs Market Segmentation
The global myelodysplastic syndrome drugs market is segmented by type, type of syndrome, route of administration, and end-user.
By type, it is segmented into immunomodulatory drugs, chemotherapy, and others. The chemotherapy segment is sub-segmented into hypomethylating drugs and conventional drugs. On the other hand, immunomodulatory drugs are further divided into thalidomide and lenalidomide.
By type of syndrome, it is segmented into refractory cytopenia with multilineage dysplasia, refractory anemia with ringed sideroblasts, refractory cytopenia with excess blasts, refractory cytopenia, and others.
By route of administration, it is segmented into parenteral, oral, and others.
By end-user, it is segmented into ambulatory surgical centers, hospitals, clinics, and others. The hospitals segment is expected to contribute the maximum to the global market net earnings owing to the capability of doctors at hospitals for dealing with a large number of MDS patients.
Myelodysplastic Syndrome (MDS) Drugs Market Regional Analysis
The Middle East & Africa (MEA), Europe, Asia Pacific (APAC), and North America are the main regions considered during the compilation of the market report.
The Americas are touted to reign in the top position in the global MDS drugs market till 2025 due to the high prevalence of patients detected with the disease. According to the American Society of Clinical Oncology in 2019, nearly 10,000 patients are detected with MDS annually.
The APAC MDS drugs market is projected to showcase a massive growth rate due to the large wherewithal in research and development activities. Clinical studies are one of the biggest drivers of the market, with one famous study claiming the different types of cancers affecting patients according to their race.
The European region can be a lucrative area for the global myelodysplastic syndrome drugs market due to approvals from regulatory agencies and clinical studies pinpointing the root causes in genotypes of patients in the region.
